{"count": 3, "results": [{"_id": "34555978", "pmid": 34555978, "title": "Emerging agents for the treatment and prevention of stroke: progress in clinical trials.", "journal": "Expert Opin Investig Drugs", "authors": ["Safouris A", "Magoufis G", "Tsivgoulis G"], "date": "2021-10-01T00:00:00Z", "doi": "10.1080/13543784.2021.1985463", "meta_date_publication": "2021 Oct", "meta_volume": "30", "meta_issue": "10", "meta_pages": "1025-1035", "score": 50222.58, "text_hl": "ABBREVIATIONS: IVT: intravenous thrombolysis; RCTs: randomized-controlled clinical trials; TNK: Tenecteplase; @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@COVID-19@@@: @DISEASE_COVID_19 @DISEASE_MESH:D000086382 @@@Coronavirus 2019 Disease@@@; EXTEND-IA TNK: The Tenecteplase versus Alteplase Before Endovascular Therapy for @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@Ischemic Stroke@@@ trial; @DISEASE_Androgen_Insensitivity_Syndrome @DISEASE_MESH:D013734 @@@AIS@@@: @DISEASE_Ischemic_Stroke @DISEASE_MESH:D000083242 @@@acute ischemic stroke@@@; NNT: number needed to treat; MT: mechanical thrombectomy; sICH: symptomatic @DISEASE_Intracranial_Hemorrhages @DISEASE_MESH:D020300 @@@intracranial hemorrhage@@@; mRS: modified Rankin Scale; AHA/@CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@ASA@@@: American Heart Association/American @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ Association; ESO: European @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ Organization; NA-1: @CHEMICAL_Tat_NR2B9c @CHEMICAL_MESH:C542597 @@@Nerinetide@@@; ENACT: Evaluating Neuroprotection in @DISEASE_Aneurysm @DISEASE_MESH:D000783 @@@Aneurysm@@@ Coiling Therapy; CTA: CT angiography; @DISEASE_Ischemic_Attack_Transient @DISEASE_MESH:D002546 @@@TIA@@@: @DISEASE_Ischemic_Attack_Transient @DISEASE_MESH:D002546 @@@transient ischemic attack@@@; CHANCE: @CHEMICAL_Clopidogrel @CHEMICAL_MESH:D000077144 @@@Clopidogrel@@@ in High-risk @SPECIES_9606 @@@patients@@@ with Acute Non-disabling @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@Cerebrovascular Events@@@; LOF: loss-of-function; PRINCE: Platelet Reactivity in Acute Nondisabling @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@Cerebrovascular Events@@@; THALES: Acute @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ or @DISEASE_Ischemic_Attack_Transient @DISEASE_MESH:D002546 @@@Transient Ischemic Attack@@@ Treated with @CHEMICAL_Ticagrelor @CHEMICAL_MESH:D000077486 @@@Ticagrelor@@@ and @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@ASA@@@ [@CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@acetylsalicylic acid@@@] for Prevention of @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ and @DISEASE_Death @DISEASE_MESH:D003643 @@@Death@@@; CHANCE-2: @CHEMICAL_Clopidogrel @CHEMICAL_MESH:D000077144 @@@Clopidogrel@@@ With @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@Aspirin@@@ in High-risk @SPECIES_9606 @@@Patients@@@ With Acute Non-disabling @DISEASE_Cerebrovascular_Disorders @DISEASE_MESH:D002561 @@@Cerebrovascular Events@@@ II; FXI: Factor XI; PACIFIC-@DISEASE_Stroke @DISEASE_MESH:D020521 @@@STROKE@@@: Program of Anticoagulation via Inhibition of FXIa by the Oral Compound BAY 2433334-NonCardioembolic @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ study; COMPASS: Cardiovascular Outcomes for People Using Anticoagulation Strategies; CANTOS-ICAD: Combination Antithrombotic Treatment for Prevention of Recurrent @DISEASE_Cerebral_Infarction @DISEASE_MESH:D002544 @@@Ischemic Stroke@@@ in Intracranial Atherosclerotic Disease; SAMMPRIS: Stenting and Aggressive Medical Therapy for Preventing Recurrent @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ in @<m>DISEASE_Constriction_Pathologic</m> @DISEASE_MESH:D003251 @@@Intracranial Stenosis@@@; WASID: @CHEMICAL_Warfarin @CHEMICAL_MESH:D014859 @@@Warfarin@@@-@CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@Aspirin@@@ Symptomatic @DISEASE_Intracranial_Arterial_Diseases @DISEASE_MESH:D020765 @@@Intracranial Disease@@@; SPARCL: @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ Prevention by Aggressive Reduction in @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Levels; LDL-C: low-density lipoprotein cholesterol; TST: Treat @DISEASE_Stroke @DISEASE_MESH:D020521 @@@Stroke@@@ to Target; IMPROVE-IT: Improved Reduction of Outcomes: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Vytorin@@@ Efficacy International Trial; @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@: proprotein convertase subtilisin-kexin type 9; FOURIER: Further Cardiovascular Outcomes Research with @GENE_PCSK9 @GENE_255738 @@@PCSK9@@@ Inhibition in Subjects with Elevated Risk; CLEAR: @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@Cholesterol@@@ Lowering via @CHEMICAL_8_hydroxy_2_2_14_14_tetramethylpentadecanedioic_acid @CHEMICAL_MESH:C581236 @@@Bempedoic acid@@@, an ACL-inhibiting Regimen; REDUCE-IT: Reduction of Cardiovascular Events With EPA Intervention Trial; STRENGTH: Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk @SPECIES_9606 @@@PatienTs@@@ With @DISEASE_Hypertriglyceridemia @DISEASE_MESH:D015228 @@@Hypertriglyceridemia@@@; ACCORD: Action to Control Cardiovascular Risk in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@; ADVANCE: Action in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ and @DISEASE_Vascular_Diseases @DISEASE_MESH:D014652 @@@Vascular Disease@@@: Preterax and @CHEMICAL_Gliclazide @CHEMICAL_MESH:D005907 @@@Diamicron@@@ Modified Release Controlled Evaluation; VADT: Veterans Affairs @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@ Trial; GLP-1R: @GENE_GLP1R @GENE_2740 @@@Glucagon-like peptide-1 receptor@@@; @GENE_SLC5A2 @GENE_6524 @@@SGLT2@@@: sodium-glucose cotransporter 2; CONVINCE: COlchicine for preventioN of Vascular Inflammation in Non-CardioEmbolic @DISEASE_Stroke @DISEASE_MESH:D020521 @@@stroke@@@; PROBE: Prospective Randomized Open-label Blinded Endpoint assessment.", "citations": {"NLM": "Safouris A, Magoufis G, Tsivgoulis G. Emerging agents for the treatment and prevention of stroke: progress in clinical trials. Expert Opin Investig Drugs. 2021 Oct;30(10):1025-1035. PMID: 34555978", "BibTeX": "@article{34555978, title={Emerging agents for the treatment and prevention of stroke: progress in clinical trials.}, author={Safouris A and Magoufis G and Tsivgoulis G}, journal={Expert Opin Investig Drugs}, volume={30}, number={10}, pages={1025-1035}}"}}, {"_id": "20436707", "pmid": 20436707, "pmcid": "PMC2858830", "title": "Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model", "journal": "J Korean Med Sci", "authors": ["Cho JS", "Jeong MH", "Sim DS", "Hong YJ", "Lim KS", "Kim JH", "Kim HD", "Baek JY", "Yoon HJ", "Her SH", "Jin SW", "Kim JH", "Ahn Y", "Cho JG", "Park JC", "Kang JC"], "date": "2010-05-01T00:00:00Z", "doi": "10.3346/jkms.2010.25.5.716", "meta_date_publication": "2010 May", "meta_volume": "25", "meta_issue": "5", "meta_pages": "716-22", "score": 50051.18, "text_hl": "Fifteen @SPECIES_9823 @@@pigs@@@ were taken 10/20 mg of @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ and eight @SPECIES_9823 @@@pigs@@@ were not taken @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S.@@@ Histopathologic analysis was assessed at 28 days after stenting. ", "citations": {"NLM": "Cho JS, Jeong MH, Sim DS, Hong YJ, Lim KS, Kim JH, Kim HD, Baek JY, Yoon HJ, Her SH, Jin SW, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model J Korean Med Sci. 2010 May;25(5):716-22. PMID: 20436707", "BibTeX": "@article{20436707, title={Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model}, author={Cho JS and Jeong MH and Sim DS and Hong YJ and Lim KS and Kim JH and Kim HD and Baek JY and Yoon HJ and Her SH and Jin SW and Kim JH and Ahn Y and Cho JG and Park JC and Kang JC}, journal={J Korean Med Sci}, volume={25}, number={5}, pages={716-22}}"}}, {"_id": "21321152", "pmid": 21321152, "title": "Outcome of patients with low-gradient \"severe\" aortic stenosis and preserved ejection fraction.", "journal": "Circulation", "authors": ["Jander N", "Minners J", "Holme I", "Gerdts E", "Boman K", "Brudi P", "Chambers JB", "Egstrup K", "Kesäniemi YA", "Malbecq W", "Nienaber CA", "Ray S", "Rossebø A", "Pedersen TR", "Skjærpe T", "Willenheimer R", "Wachtell K", "Neumann FJ", "Gohlke-Bärwolf C"], "date": "2011-03-01T00:00:00Z", "doi": "10.1161/CIRCULATIONAHA.110.983510", "meta_date_publication": "2011 Mar 1", "meta_volume": "123", "meta_issue": "8", "meta_pages": "887-95", "score": 50046.582, "text_hl": "We therefore evaluated the outcome of @SPECIES_9606 @@@patients@@@ with low-gradient \"severe\" @<m>DISEASE_Constriction_Pathologic</m> @DISEASE_MESH:D003251 @@@stenosis@@@ (defined as @DISEASE_Aortic_Valve_Stenosis @DISEASE_MESH:D001024 @@@aortic valve@@@ area < 1.0 cm2 and mean gradient <= 40 mm Hg) in the prospective @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Simvastatin and Ezetimibe@@@ in @DISEASE_Aortic_Valve_Stenosis @DISEASE_MESH:D001024 @@@Aortic Stenosis@@@ (SEAS) study. ", "citations": {"NLM": "Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebø A, Pedersen TR, Skjærpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Bärwolf C. Outcome of patients with low-gradient \"severe\" aortic stenosis and preserved ejection fraction. Circulation. 2011 Mar 1;123(8):887-95. PMID: 21321152", "BibTeX": "@article{21321152, title={Outcome of patients with low-gradient \"severe\" aortic stenosis and preserved ejection fraction.}, author={Jander N and Minners J and Holme I and Gerdts E and Boman K and Brudi P and Chambers JB and Egstrup K and Kesäniemi YA and Malbecq W and Nienaber CA and Ray S and Rossebø A and Pedersen TR and Skjærpe T and Willenheimer R and Wachtell K and Neumann FJ and Gohlke-Bärwolf C}, journal={Circulation}, volume={123}, number={8}, pages={887-95}}"}}]}